Key result
Prolonging dual antiplatelet therapy beyond 12 months in high-risk patients after acute coronary syndrome reduces ischemic events (NNT 46 at 3 years) but increases bleeding risk.
Why the study?
Does altering the duration of DAPT (shorter or longer than 12 months) optimize the balance between ischemic and bleeding events in patients after ACS or PCI?
Does altering the duration of DAPT (shorter or longer than 12 months) optimize the balance between ischemic and bleeding events in patients after ACS or PCI?
Answers are grounded in this paper and cite their sources.
The optimal duration of DAPT after ACS and PCI requires an individualized approach, balancing the reduced ischemic risk of prolonged therapy against the reduced bleeding risk of shorter therapy.
Introduction Dual antiplatelet treatment (DAPT) entered, in 2016, the 20-year anniversary since the publication of the initial data establishing its superiority over anticoagulation treatment in patients after percutaneous coronary angioplasty (PCI). Since then, there has been important advancement both in interventional cardiology and in pharmacological treatments. New and more powerful P2Y12 receptor inhibitors have been introduced, as well as first and then second-generation drug-eluting stents (DES), and more recently bioabsorbable stents, which revolutionized the field of percutaneous revascularization. For many years, the duration of DAPT has not been the subject of scientific debate. Through the years, when late intrastent thrombosis became an issue, attention was then directed on the duration of combined therapy with aspirin and P2Y12 receptor antagonists. In the meantime, the stent technology has rapidly progressed with the introduction of new-generation DES, characterized by thinner stent struts, lower dose of eluted drugs and more biocompatible polymers, now even biodegradable. Accordingly, the new DES are today standard of therapy, and the duration of DAPT is an important topic of discussion. Patients after acute coronary syndrome (ACS) are still at high ischemic risk, with a recurrence rate of 3–5% during the first 12 months, suggesting that prolonging DAPT after the first year could lead to reduction of ischemic complications.1 Such a strategy, unfortunately, has a significant downfall, that is the increased bleeding events. On the other hand, technological progress in the design and production of the new-generation DES, with better struts design, composition and quality of the polymers, and the pharmacokinetic of the release of the antiproliferative drug, allows a better and more rapid re-endothelization, thus reducing the risk of intrastent thrombosis, providing the rational for a shorter duration of DAPT. Presently the ESC and ACC/AHA Guidelines recommend a duration of 12 months for DAPT after ACS, regardless of the type of stent used; on the other hand, for stable patients, 1 month's duration of treatment for bare metal stent (BMS), and 6 months for DES are suggested. Nonetheless, the guidelines make provision for a longer or shorter duration of the dual therapy, according to the ischemic and bleeding risk of the patient. Two apparently contrasting questions have characterized the investigation on the duration of DAPT: on one hand, the goal has been to evaluate whether shortening the duration of treatment in patients after PCI would lead to a reduction of bleeding events without increasing thrombotic events, thus focusing on stent-related events; on the other, more in the realm of secondary prevention, whether prolonging DAPT would result in a reduction of non-stent-related ischemic events. Up to the present five randomized trials have investigated the short-term DAPT stategy.2–6 The Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT)2 study addressed the noninferiority of a 6-month versus a 12-month DAPT strategy in patients after first-generation or second-generation DES implants: 1443 patients were enrolled in the study, approximately half of them after ACS. The study proved a noninferiority for the 6-month strategy as far as the primary end-point [cardiac death, myocardial infarction, target lesion revascularization (TLR), regardless of the clinical presentation or the type of stent implanted (P for interaction 0.15–0.18 respectively)]. The bleeding complications were similar among the two groups, but the 6-month strategy was associated with a higher incidence of ischemic events in diabetic patients. The Second-Generation Drug-Eluting Stent Implantation Followed by Six- Versus Twelve-Month Dual Antiplatelet Therapy (SECURITY)3 trial enrolled 1339 patients with stable or unstable (38.4%) angina, treated with new-generation DES. The results were similar for the two DAPT strategies (6 versus 12 months) both in terms of ischemic and bleeding complications. The Safety And EFficacy of 6 Months Dual Antiplatelet Therapy After Drug-Eluting Stenting (ISAR-SAFE) Trial,4 discontinued early, demonstrated, in a total population of 4000 patients (40% after ACS), the noninferiority of the 6-month DAPT strategy as fast as the primary composite end-point (death, myocardial infarction, certain or presumed intrastent thrombosis, stroke, and major bleeding episodes according to thrombolysis in myocardial infarction (TIMI) score), regardless of the clinical presentation or the type of stent used. The RESET Trial (REal Safety and Efficacy of 3-month dual antiplatelet therapy following endeavor zotarolimus-eluting stent implantation)5 and OPTIMIZE (Three vs Twelve Months of Dual Antiplatelet Therapy After Zotarolimus-Eluting Stents The OPTIMIZE Randomized Trial)6 trials compared a 3-month DAPT versus a 12-month strategy, failing to produce significant differences in terms of ischemic or bleeding events. The population with ACS was 45 and 30% in the two studies, respectively. The RESET trial, though, demonstrated that patients after ACS treated with a 3-month DAPT had a higher, but nonsignificant, incidence of adverse cardiovascular events [death, myocardial infarction, intrastent thrombosis, TLR, or bleeding], and specifically, higher and significant incidence of TLR. A meta-analysis by Giustino et al.7 including 32 135 patients showed that a 6-month DAPT strategy was associated with higher incidence of intrastent thrombosis as compared with a 12-month strategy, but with a lower incidence of major bleeding events according to the TIMI score; furthermore, the noted higher incidence of intrastent thrombosis decreased when new-generation DES were used. A different meta-analysis by Giustino et al.8 including 9577 patients after PCI, compared a 3-to-6-month DAPT (clopidogrel and aspirin) to a 12-month strategy; 1680 underwent high complexity PCI (trivessels PCI, ≥3 stents implanted, ≥3 lesions PCI, bifurcation PCI with ≥2 stent implanted, stented segment >60 mm, chronic occlusion). Patients after complex PCI had an almost double risk of major cardiovascular events. Compared with short-term DAPT, the ≥12-month strategy provided a significant reduction of major cardiovascular events for patients after complex PCI. The extent of the benefit of prolonged DAPT was progressively more evident as the complexity of the PCI increased. Nonetheless, prolonged DAPT was associated with an excess of major bleeding episodes. Present guidelines recommend shorter DAPT only for patients at high risk for bleeding (oral anticoagulation or after major intracranial surgery), or in those patients who develop a major bleeding episode; in particular, in patients after ACS at high risk for bleeding, the American Guidelines recommend a 6-month course, and the European Guidelines a 3–6-month course of DAPT. A similar debate surrounds the strategy of prolonged DAPT beyond 12 months. Six randomized trials have addressed this issue.9–14 Unfortunately, most of them involved medium-sized or small population samples,9,10,12,13 and the patients did not have either ischemic or bleeding events during the first year, and were then defined as low risk.9–14 The Late Coronary Arterial Thrombotic Event (DES LATE) trial,9 The ARCTIC (Assessment by a double Randomisation of a Conventional antiplatelet strategy versus a monitoring-guided strategy for drug-eluting stent implantation and, of Treatment Interruption versus Continuation 1 year after stenting)-Interruption trial-interruption,10 The ITALIC (Is There A LIfe for DES after Discontinuation of Clopidogrel) trial,12 and OPTIDUAL13 trials failed to demonstrate a clinical benefit or increase bleeding risk for prolonged DAPT. The PRODIGY11 and ITALIC12 studies, instead, compared the 6-versus 12-month DAPT regimens. Valgimigli et al., in the PRODIGY study,11 randomized 1970 patients after implantation of four different stents [BMS, DES with paclitaxel (PES), DES with everolimus (EES) and DES with zotarolimus (ZES)], with a 2-year follow-up. The incidence of the cumulative primary end-point (death, myocardial infarction, stroke) was similar for the two strategies (6 versus 24 months), but patients receiving DAPT for 24 months had twice the bleeding events (bleeding types 5, 3, or 2 according to the BARC criteria). According to the prespecified stent analysis,15 the various stents behave differently (P for interaction = 0.003). Patients receiving the ZES had a high ischemic risk following the 24-month DAPT, whether patients treated with PES or EES benefited from this treatment strategy. The DAPT14 trial enrolled patients without adverse events in the first 12 months after treatment, and compared the discontinuation of the dual therapy after 12 months versus its continuation for further 18 months with a thienopyridines (65% clopidogrel, 35% prasugrel) and aspirin. The trial population included 62% of patients after ACS. The prolonged DAPT strategy (30 months total) reduced significantly the co-primary ischemic end-point (certain or probable intrastent thrombosis, death, myocardial infarction, stroke). Furthermore, the clinical benefit was not device-related (thus not related to intrastent thrombosis), reducing the risk of myocardial infarction by 55%. The risk of myocardial infarction, both stent-related and not, was higher during the first 3 months after the withdrawal of DAPT, both for the 12- and 30-month arm of the study. There was also an interaction between major cardiovascular or cerebrovascular events and type of stent implanted (P for interaction 0.048); in particular, patients receiving first-generation DES benefited more from the 30-month strategy than patients treated with newer DES. For the former group of patients the relative risk reduction of cardiovascular or cerebrovascular events was 50%. For patients receiving EES, the 30-month protocol reduced intrastent thrombosis and myocardial infarction, but not major cardiovascular or cerebrovascular events.16 Patients treated with BMS, instead, did not derive any advantages in terms of reduction of intrastent thrombosis or major cardiovascular or cerebrovascular events.17 The 30-month strategy was also more beneficial for patients with previous myocardial infarction,18 but associated with an increased moderate or severe bleeding episode according to the GUSTO criteria. Another interesting aspect relates to all-cause mortality: this was higher for the 30-month arm, and related to noncardiovascular causes, but perhaps to an increased incidence of malignancies occurring after randomization. The trauma-related mortality was also higher for the 30-month arm of the study. A task force (joint ACC and AHA)19 revision committee report, including six trials,9–14 concluded that a prolonged DAPT strategy (18–48 months) reduced the study primary end-point as well as intrastent thrombosis, but increased major bleeding events. Furthermore, prolonged DAPT did not increase the all-cause mortality. The PEGASUS-TIMI-5420 trial was design to evaluate the efficacy and safety of a combination of aspirin and ticagrelor (at two different doses), in patients more than 50 years old, with previous myocardial infarction (1–3 years before enrolment), and at least one further risk factor (age >65 years, diabetes mellitus, a second previous myocardial infarction, multivessel coronary disease, chronic renal insufficiency). The study population included 21 162 patients and was randomized to receive ticagrelor 90 or 60 mg b.i.d. versus placebo, as well as aspirin. During a 3-year follow-up, double therapy reduced the primary end-point (cardiovascular death, myocardial infarction, and stroke) significantly. Both doses of ticagrelor increased the bleeding episodes, less with the 60 mg b.i.d. dose. Nevertheless, the use of ticagrelor was not associated with increase in fatal bleeding episodes, cerebral hemorrhage, or all-cause mortality. The 60-mg dose also had a lower incidence of dyspnea, which often determines the discontinuation of this drug. A prespecified analysis21 suggested a further advantage for prolonging DAPT without interruption, by showing a reduction of ischemic events for patients with uninterrupted therapy with P2Y12 receptor inhibitor, or for those who terminated the treatment for 30 days or less, with a number-needed-to treat of 46 in 3 years. This advantage was less secure when the drug had been withdrawn for more than 30 days but for less than 1 year, and was lost when the drug was suspended for more than 1 year. Notwithstanding the encouraging result of the PEGASUS-TIMI-54 study, the risk/benefits ratio of a prolonged DAPT is negligible for stable patients with a distant history (>1 year) of myocardial infarction according to the ACC/AHA revision committee.19 Based on these observations the recently updated American Guidelines22 recommend continuation of DAPT beyond 12 months in patients who tolerated the treatment without developing bleeding complications and who are not at high bleeding risk. In September 2016, the Società Italiana di Cardiologia released a document on the optimal duration of DAPT.23 The key message has been the need to personalize the treatment, considering the risk and benefits of the treatment vis-à-vis the ischemic and bleeding risk, not just at the beginning, but also during the course of the treatment, because the risk/benefit ratio could change in time. Considering the data from the PEGASUS-TIMI-54, extending the DAPT treatment over the first 12 months is recommended in patients after ACS at high ischemic risk utilizing ticagrelor 60 mg b.i.d.; on the other hand, the treatment is not recommended for patients at high bleeding risk, thus stressing further the individualized approach. To facilitate the clinical application of these concepts, the use of ischemic score systems (e.g. DAPT score and PARIS score), as well as bleeding risk score (e.g. HAS-BLED) has been recommended. These scoring systems are useful in assessing the prognosis of the patient, but they are not always validated (e.g. DAPT score), and their impact in clinical practice has yet to be proven on a large scale. Even more controversial is the definition of ‘individualized strategy’, which is, in daily clinical practice, the most sensible, focusing on the individual patient's specificities. One of the most insidious risks is to base our decision on the ‘stent-device’, rather than on the patient with ischemic heart disease. In fact, the clinical benefits of a prolonged DAPT strategy are not only in the realm of stent-related ischemic events, but are evident in patients receiving both first-generation and second-generation stents, as shown by the DAPT14 study. Accordingly, a short-term DAPT could be less than optimal for patients treated with newer DES. The benefits of prolonging DAPT is more evident in patients with a previous myocardial infarction, but in these patients, as well, the treatment should be recommended on a case-by-case basis, paying particular attention to patients at high risk for bleeding. There is a not negligible number of patients with ACS (5–7%) affected with nonobstructive coronary artery disease. Often those are young, African American female patients. Data regarding this condition are few and often discordant. The annual rate of recurrences is 1–2%24; nonetheless, a retrospective analysis of the study ACUITY25 demonstrated that these patients had a worst prognosis in terms of mortality than patients with obstructive coronary disease. The pathophysiology of ACS when coronary arteries are without critical stenosis is highly variable, and includes vasospasm, microvascular dysfunction, Kounis syndrome, coronary embolization, cocaine abuse, severe anemia, and hypertensive crises. Often the treatment of these patients is at variance from ‘classical’ ACS, and should focus on the underlying pathophysiology. Vasodilator drugs are first line treatment in vasospasm, while beta-blockers should be avoided in this situation, as well as when ACS is secondary to cocaine abuse. Even though data are limited there is no evidence to support DAPT in these patients; rather, it is important to determine the cause of the syndrome and implement the appropriate treatment in a timely fashion. Acknowledgements Conflicts of interest There are no conflicts of interest.
No takes yet. Share an insight, caveat, or question.
Grotti et al. (2018) conducted a review in Acute coronary syndrome. Dual antiplatelet therapy (DAPT) was evaluated. Prolonging dual antiplatelet therapy beyond 12 months in high-risk patients after acute coronary syndrome reduces ischemic events (NNT 46 at 3 years) but increases bleeding risk.
Synapse has enriched 10 related papers. Consider them for comparative context: